Identificador persistente para citar o vincular este elemento: http://hdl.handle.net/10553/136180
Campo DC Valoridioma
dc.contributor.authorArévalo Lorido, José Carlosen_US
dc.contributor.authorCarretero Gómez, Juanaen_US
dc.contributor.authorConde Martel, Aliciaen_US
dc.contributor.authorAramburu Bodas, Oscaren_US
dc.contributor.authorTrullás, Joan Carlesen_US
dc.contributor.authorCarrasco Sánchez, Francisco Javieren_US
dc.contributor.authorManzano Espinosa, Luisen_US
dc.contributor.authorCerqueiro González, Jose Manuelen_US
dc.contributor.authorMoreno García, Carmenen_US
dc.contributor.authorCasado Cerrada, Jesúsen_US
dc.contributor.authorMontero Pérez-Barquero, Manuelen_US
dc.date.accessioned2025-02-13T16:46:10Z-
dc.date.available2025-02-13T16:46:10Z-
dc.date.issued2024en_US
dc.identifier.issn0300-7995en_US
dc.identifier.urihttp://hdl.handle.net/10553/136180-
dc.description.abstractObjective: Two profiles of patients with heart failure with preserved ejection fraction (HFpEF) and type 2 diabetes mellitus (T2DM) can be discerned: those with ischemic and those with diabetic cardiomyopathy (DMC). We aim to analyze clinical differences and prognosis between patients of these two profiles. Material and methods: This cohort study analyzes data from the Spanish Heart Failure Registry, a multicenter, prospective registry that enrolled patients admitted for decompensated heart failure and followed them for one year. Three groups were created according to the presence of T2DM and heart disease depending on the etiology (ischemic when coronary artery disease was present, or DMC when no coronary, valvular, or congenital heart disease; no hypertension; nor infiltrative cardiovascular disease observed on an endomyocardial biopsy). The groups and outcomes were compared. Results: A total of 466 patients were analyzed. Group 1 (n = 210) included patients with ischemic etiology and T2DM. Group 2 (n = 112) included patients with DMC etiology and T2DM. Group 3 (n = 144), a control group, included patients with ischemic etiology and without T2DM. Group 1 had more hypertension and dyslipidemia; group 2 had more atrial fibrillation (AF) and higher body mass index; group 3 had more chronic kidney disease and were older. In the regression analysis, group 3 had a better prognosis than group 1 (reference group) for cardiovascular mortality and HF readmissions (HR 0.44;95%CI 0.2–1; p =.049). Conclusions: Patients with T2DM and HFpEF, who had the poorest prognosis, were of two different profiles: either ischemic or DMC etiology. The first had a higher burden of cardiovascular disease and inflammation whereas the second had a higher prevalence of obesity and AF. The first had a slightly poorer prognosis than the second, though this finding was not significant.en_US
dc.languageengen_US
dc.relation.ispartofCurrent Medical Research and Opinionen_US
dc.sourceCurrent Medical Research and Opinion [ISSN 0300-7995], v. 40 (3), pp. 359-366en_US
dc.subject32 Ciencias médicasen_US
dc.subject3205 Medicina internaen_US
dc.subject320502 Endocrinologíaen_US
dc.subject320501 Cardiologíaen_US
dc.subject.otherCoronary artery diseaseen_US
dc.subject.otherDiabetic cardiomyopathyen_US
dc.subject.otherDiabetic cardiomyopathyen_US
dc.subject.otherHeart failure preserved ejection fractionen_US
dc.subject.otherType 2 diabetes mellitusen_US
dc.titleThe two different profiles in heart failure with preserved ejection fraction and type 2 diabetes mellitus: ischemic and diabeticen_US
dc.typeArticleen_US
dc.identifier.doi10.1080/03007995.2024.2303089en_US
dc.identifier.pmid38193461-
dc.identifier.scopus2-s2.0-85184708734-
dc.contributor.orcid#NODATA#-
dc.contributor.orcid#NODATA#-
dc.contributor.orcid#NODATA#-
dc.contributor.orcid#NODATA#-
dc.contributor.orcid#NODATA#-
dc.contributor.orcid#NODATA#-
dc.contributor.orcid#NODATA#-
dc.contributor.orcid#NODATA#-
dc.contributor.orcid#NODATA#-
dc.contributor.orcid#NODATA#-
dc.contributor.orcid#NODATA#-
dc.description.lastpage366en_US
dc.identifier.issue3-
dc.description.firstpage359en_US
dc.relation.volume40en_US
dc.investigacionCiencias de la Saluden_US
dc.type2Artículoen_US
dc.utils.revisionen_US
dc.identifier.ulpgcen_US
dc.contributor.buulpgcBU-MEDen_US
dc.description.sjr0,712
dc.description.jcr2,3
dc.description.sjrqQ2
dc.description.jcrqQ3
dc.description.scieSCIE
dc.description.miaricds11,0
item.fulltextCon texto completo-
item.grantfulltextopen-
crisitem.author.deptGIR IUIBS: Patología y Tecnología médica-
crisitem.author.deptIU de Investigaciones Biomédicas y Sanitarias-
crisitem.author.deptDepartamento de Ciencias Médicas y Quirúrgicas-
crisitem.author.orcid0000-0002-2540-3880-
crisitem.author.parentorgIU de Investigaciones Biomédicas y Sanitarias-
crisitem.author.fullNameConde Martel, Alicia-
Colección:Artículos
Adobe PDF (1,15 MB)
Vista resumida

Citas SCOPUSTM   

1
actualizado el 16-feb-2025

Google ScholarTM

Verifica

Altmetric


Comparte



Exporta metadatos



Los elementos en ULPGC accedaCRIS están protegidos por derechos de autor con todos los derechos reservados, a menos que se indique lo contrario.